morphosys

  1. T

    MorphoSys Receives Research Grant To Advance Anti-CD38 Cancer Program MOR202 And Expl

    MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced that it has been awarded a grant by the German Federal Ministry of Education and Research, BMBF. The funding of approximately EUR 1 million supports MorphoSys in accelerating the development of its HuCAL-based cancer program...
Back
Top